Bank of Japan Poised for Historic Rate Hike as Inflation Pressures Persist 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Singapore Growth Outlook Brightens for 2025 as Economists Flag AI and Geopolitical Risks 
Asian Stocks Slide as AI Valuation Fears and BOJ Uncertainty Weigh on Markets 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Bank of Korea Downplays Liquidity’s Role in Weak Won and Housing Price Surge 
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
South Korea Warns Weak Won Could Push Inflation Higher in 2025 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
U.S. Dollar Slips Near Two-Month Low as Markets Await Key Jobs Data and Central Bank Decisions 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
U.S. Dollar Steadies Near October Lows as Rate Cut Expectations Keep Markets on Edge 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
